Literature DB >> 2230113

Activation of murine T cells by streptococcal pyrogenic exotoxin type A. Requirement for MHC class II molecules on accessory cells and identification of V beta elements in T cell receptor of toxin-reactive T cells.

K Imanishi1, H Igarashi, T Uchiyama.   

Abstract

We investigated the mechanisms of murine T cell activation by streptococcal pyrogenic exotoxin type A (SPE A), focusing on the role of MHC class II molecules on accessory cells (AC) and V beta usage in alpha beta TCR of SPE A-reactive T cells in comparison with staphylococcal enterotoxin B-reactive T cells. L cells transfected with I-Ab genes functioned as effective AC for SPE A-induced responses by C57BL/6 T cells, proliferation, and IL-2 production, but control L cells were not effective AC. Anti-I-Ab mAb inhibited the SPE A-induced responses. Staphylococcal enterotoxin B-induced C57BL/6 T cell blasts were composed of cells bearing V beta 3, members of the V beta 8 family, and V beta 11. Most of the SPE A-induced T cell blasts (about 80%) bore V beta 8.2. mAb reactive to V beta 8.2 markedly inhibited SPE A-induced T cell responses. Apparently, SPE A activates mainly T cells bearing V beta 8.2 in physical association with MHC class II molecules expressed on AC. We also discuss the pathogenic activities of SPE A in relation to toxic shock syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230113

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Feedback suppression of staphylococcal enterotoxin-stimulated T-lymphocyte proliferation by macrophages through inductive nitric oxide synthesis.

Authors:  K Isobe; I Nakashima
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

2.  Relative abilities of distinct isotypes of human major histocompatibility complex class II molecules to bind streptococcal pyrogenic exotoxin types A and B.

Authors:  K Imanishi; H Igarashi; T Uchiyama
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

3.  Biological properties of staphylococcal enterotoxin-like toxin type R.

Authors:  Katsuhiko Omoe; Ken'ichi Imanishi; Dong-Liang Hu; Hidehito Kato; Hiromi Takahashi-Omoe; Akio Nakane; Takehiko Uchiyama; Kunihiro Shinagawa
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

4.  Distinct T-cell receptor V beta gene usage by human T lymphocytes stimulated with the streptococcal pyrogenic exotoxins and pep M5 protein.

Authors:  M A Tomai; P M Schlievert; M Kotb
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

5.  Characterization of novel staphylococcal enterotoxin-like toxin type P.

Authors:  Katsuhiko Omoe; Ken'ichi Imanishi; Dong-Liang Hu; Hidehito Kato; Yoshitaku Fugane; Yohei Abe; Shoji Hamaoka; Yutaka Watanabe; Akio Nakane; Takehiko Uchiyama; Kunihiro Shinagawa
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity.

Authors:  Glen C Ulett; Elisabeth E Adderson
Journal:  Curr Immunol Rev       Date:  2006-05

Review 7.  Bacterial and viral superantigens: roles in autoimmunity?

Authors:  H Acha-Orbea
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

8.  The Mycoplasma arthritidis superantigen MAM: purification and identification of an active peptide.

Authors:  C L Atkin; S Wei; B C Cole
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Cytokine induction by extracellular products of oral viridans group streptococci.

Authors:  H Takada; Y Kawabata; M Tamura; K Matsushita; H Igarashi; H Ohkuni; Y Todome; T Uchiyama; S Kotani
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

10.  Purification and partial characterization of a product from Yersinia pseudotuberculosis with the ability to activate human T cells.

Authors:  T Miyoshi-Akiyama; K Imanishi; T Uchiyama
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.